Matthew Rettig, MD
Hematology & Oncology · Los Angeles, CANPI 1487751798
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $342,705 of the $442,034 with a category attached, or 77.5%. 21 manufacturers reported payments, led by Johnson & Johnson at 56.9% of the total. Reporting peaked in 2022 at $119,222 and has fallen 57.1% since, to $51,111 in 2025. Among hematology & oncology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 388 payments — averaging $1139.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$252K
- Bayer$174K
- Clovis Oncology, Inc.$5K
- Janssen Scientific Affairs, LLC$4K
- Novartis$2K
- Amgen$2K
- plus $4K from 15 others
Across 100 payments — averaging $77,761 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$2.5M
- Novartis$2.3M
- Amgen$2.1M
- Clovis Oncology, Inc.$409K
- Pfizer$129K
- Progenics Pharmaceuticals, Inc.$104K
- plus $182K from 4 others
What the payments were for
- Consulting fees$49,14811%
- Speaking & faculty fees$342,70578%
- Travel & lodging$44,95910%
- Food & beverage$5,1901%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 239 | $251,662 |
| Bayer | 91 | $174,123 |
| Clovis Oncology, Inc. | 2 | $4,990 |
| Janssen Scientific Affairs, LLC | 6 | $3,705 |
| Novartis | 1 | $2,025 |
| Amgen | 2 | $2,008 |
| AstraZeneca | 4 | $1,904 |
| Sanofi | 2 | $430 |
| Dendreon Pharmaceuticals LLC | 4 | $215 |
| Pfizer | 9 | $210 |
| Astellas Pharma US Inc | 2 | $158 |
| Rochester Medical Corporation | 11 | $126 |
| Progenics Pharmaceuticals, Inc. | 1 | $126 |
| Sun Pharmaceutical Industries Inc. | 5 | $123 |
| Merck | 2 | $60 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $48 |
| AVEO Pharmaceuticals, Inc. | 1 | $29 |
| Procept Biorobotics Corporation | 1 | $24 |
| Karyopharm Therapeutics Inc. | 1 | $24 |
| Gilead | 1 | $23 |
| Tactile Systems Technology Inc | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$442,034 in reported general payments places this provider in the 95th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NubeqaDarolutamide | 220 | $2,965,178 |
| XtandiEnzalutamide | 161 | $2,188,103 |
| ErleadaApalutamide | 97 | $1,418,534 |
| OrgovyxRelugolix | 125 | $337,632 |
| Abiraterone Acetate | 94 | $193,674 |
| ZytigaAbiraterone Acetate | 12 | $134,973 |
| Ibandronate Sodium | 49 | $2,345 |
| Megestrol Acetate | 22 | $1,140 |
| Prednisone | 61 | $674 |
| Tamsulosin Hcl | 19 | $444 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerNubeqa | $174,123 | $2,965,178220 claims |
| Astellas Pharma US IncXtandi | $158 | $2,188,103161 claims |
| Johnson & JohnsonErleada, Zytiga | $251,662 | $1,553,507109 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $3,705 | $193,67494 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in Los Angeles
- Dennis SlamonLos Angeles$3.1M
- George YaghmourLos Angeles$1.9M
- Kevin KellyLos Angeles$894K
- Raghuveer RanganathanLos Angeles$609K
- David BerzLos Angeles$420K
- Gottfried KonecnyLos Angeles$402K
- Antoni RibasLos Angeles$315K
- Edward GaronLos Angeles$301K
- Rahul NaikLos Angeles$297K
- Sandra HorningStanford$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.